Specialties

New study focuses on cardiovascular safety of weight loss drug in patients with excess weight or obesity.

The SUMMIT VIP study shows conventional risk factors do not suffice in predicting heart complications.

Increased risk of hemorrhage with no significant lowering of cardiovascular risk means low-dose aspirin recommendations are in peril.

No significant statistical differences found between patients with diabetes using supplement versus placebo.

Patients with type 1 diabetes and prolonged increased HbA1c were found to be at two-times greater risk for dementia than those with well-managed HbA1c values.

New findings compare treatment with patients taking two or more glucose-lowering agents.

Investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.

Recent studies show continued benefit in decreasing all-cause mortality from cardiovascular disease.

When you have female patients who have type 2 diabetes, obesity, a history of irregular periods and/or the other symptoms of PCOS, ask them about their daughters. Do they have like symptoms of PCOS, as Dr. Cobin discusses in her videos?

Rhoda H. Cobin, MD, MACE is Clinical Professor of Medicine at the Ichan School of Medicine at Mount Sinai NYC. She is a founding board member of AACE, served as its president and the president of the American College of Endocrinology. Dr. Cobin's academic interests include reproductive endocrinology, thyroid disease and thyroid cancer, and diabetes. She was one of the chairs for the production of AACe's Disease State Clincial Review : Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome. She and AACE have particularly been concerned for over a decade with increasing awareness of the significant cardiometabolic consequences of PCOS.